Scientists build a biobank to decode ARDS and personalize treatment
NCT ID NCT07675265
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study collects blood samples and health data from 1,200 adults with ARDS in intensive care. Researchers aim to identify biological markers that can group patients into subtypes and predict how they will respond to different treatments. The goal is to improve care for this life-threatening lung condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to classify ARDS subtypes and predict which treatments work best for individual patients.
- What could go wrong
- This is an observational study, not a treatment trial. The algorithms developed may not prove accurate enough for clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cell infusion aims to free ARDS patients from ventilators
- New ventilation strategy aims to reduce lung damage in severe pneumonia
- Scientists hunt for hidden ARDS subtypes to crack deadly lung failure
- Simple chest squeeze may replace High-Tech ventilator settings
- Lab study hopes to unlock ARDS treatment using patient blood cells
- New study uses imaging to see how nitric oxide helps ARDS lungs